Tesamorelin (
INN; trade name
Egrifta SV) is a
synthetic form of
growth-hormone-releasing hormone (GHRH) which is used in the treatment of
HIV-associated lipodystrophy, approved initially in 2010. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic
peptide consisting of all 44
amino acids of human GHRH with the addition of a
trans-3-hexenoic acid group.
